Esograp-DSR Capsule is a combination pharmaceutical formulation containing Domperidone 30 mg and Esomeprazole 40 mg, indicated for the management of gastroesophageal reflux disease (GERD), dyspepsia, and related upper gastrointestinal disorders. Domperidone, a peripheral dopamine D2 receptor antagonist, facilitates gastric motility and accelerates gastric emptying, thereby reducing symptoms such as nausea, vomiting, and bloating. Esomeprazole, a proton pump inhibitor (PPI), suppresses gastric acid secretion by irreversibly inhibiting the H+/K+ ATPase enzyme system in gastric parietal cells, promoting mucosal healing and symptom relief. The synergistic action of these agents provides effective control of acid-related symptoms and improves gastric motility, enhancing patient outcomes. Esograp-DSR is typically administered orally once daily, preferably before meals, with dosage adjustments based on clinical response and physician discretion. Caution is advised in patients with hepatic impairment, cardiac arrhythmias, or those on medications that may interact with Domperidone or Esomeprazole. Common adverse effects include headache, dry mouth, and gastrointestinal disturbances. This combination should be used under medical supervision, with attention to contraindications and potential drug interactions to ensure safety and efficacy in the treatment of acid-peptic disorders.

Dosage & How to Use